Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2016-11-15 AGM Information
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Chairman and CEO Presentation to Annual General Meeting 28 pages 1.2MB
AGM Information Classification · 95% confidence The document is a detailed address by the Chairman at the 2016 Annual General Meeting (AGM) of Living Cell Technologies. It includes a review of the past year's milestones, clinical trial progress, capital raising activities, and future plans. The content is typical of a Chairman's report presented at an AGM, focusing on company progress, strategy, and shareholder communication. There is no indication that this is a full Annual Report (10-K) or an earnings release, nor is it a transcript of a call or a regulatory filing. The presence of the phrase 'Chairman’s Address to the 2016 Annual General Meeting' and the nature of the content strongly indicate this is AGM Information (AGM-R). The document length (15,000 characters) and detailed content support this classification with high confidence.
2016-11-15 English
Results of Annual General Meeting 4 pages 97.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement titled 'Results of Annual General Meeting held on 16 November 2016' for Living Cell Technologies Limited. It provides detailed voting results for resolutions passed at the AGM, including adoption of the Remuneration Report, re-election of directors, approval of share option plans, and ratification of share issues. The content focuses exclusively on the voting outcomes of the AGM resolutions, referencing the meeting date and proxy votes. There is no presentation material, full financial report, or management discussion included. The document is not a full Annual Report (10-K), nor an Interim Report (IR), nor a Remuneration Report (DEF 14A) itself, but rather the official announcement of the voting results from the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length (8558 characters) is sufficient to contain detailed voting results, not just a brief notice. Therefore, the correct classification is DVA with high confidence.
2016-11-15 English
Approval granted for group 2 in Parkinsons trial 2 pages 331.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 11 November 2016. It reports the approval granted by the Data Safety Monitoring Board (DSMB) to commence treating patients in a Phase IIb clinical trial for Parkinson's disease. The content focuses on clinical trial progress, protocol amendments, and future plans for the trial and product commercialization. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The document is a corporate announcement about clinical trial progress and regulatory approval related to the trial, not a financial report or management discussion. It is not a report publication announcement since it contains substantive information about the trial status and approvals. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related updates that do not fit other specific categories.
2016-11-10 English
Appendix 4C Quarterly Cash Flow Report 30 September 2016 7 pages 636.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 30 September 2016' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, with specific figures for the quarter ended 30 September 2016. The document also includes a compliance statement confirming preparation according to accounting standards and Listing Rule 19.11A. The presence of actual financial data for a quarter, including cash flow statements and notes, indicates this is a comprehensive interim/quarterly financial report rather than a mere announcement or summary. The document length (15,000 characters) and detailed financial content confirm it is not just a report publication announcement or regulatory filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2017
2016-10-19 English
Annual Report to shareholders 44 pages 8.4MB
Annual Report Classification · 100% confidence The document is titled '2015 - 2016 ANNUAL REPORT' and contains detailed sections typical of an annual report, including Chairman's report, CEO's report, Directors' report, Auditor's independence declaration, consolidated financial statements, notes to the financial statements, directors' declaration, and independent auditor's report. It covers the full fiscal year 2015-2016 and includes comprehensive financial data and corporate information. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2016
2016-10-16 English
Notice of Annual General Meeting/Proxy Form 12 pages 507.6KB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for Living Cell Technologies Limited, specifying the date, time, and place of the meeting. It includes detailed agenda items such as consideration of the Financial Report for the year ended 30 June 2016, adoption of the Remuneration Report, re-election of directors, and other shareholder resolutions. The text also references voting exclusions and explanatory notes related to the AGM. There is no actual financial data or full report content included; rather, it is a notice and agenda for the meeting. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document is lengthy (15,000 characters) but is clearly a notice and agenda, not the full Annual Report or other filings. Therefore, the correct classification is AGM-R with high confidence.
2016-10-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.